|
Total Revenue
|
|
$133.5m
|
$160.6m
|
$173.1m
|
$209.5m
|
$334.8m
|
$415.7m
|
$464.8m
|
$335.1m
|
|
Revenues from contracts with customers
|
|
$133.5m
|
$160.3m
|
$172.4m
|
$206.7m
|
$328.5m
|
$419.4m
|
$464.8m
|
$333.3m
|
|
Cost of Goods and Services Sold
|
|
($77.1m)
|
$87.0m
|
$93.6m
|
$118.6m
|
$208.4m
|
$235.5m
|
$278.2m
|
$203.4m
|
|
Cost of sales
|
|
($77.1m)
|
($87.0m)
|
($93.6m)
|
($118.6m)
|
($208.4m)
|
($235.5m)
|
($278.2m)
|
($203.4m)
|
|
Gross Profit (derived)
|
|
$56.4m
|
$73.6m
|
$79.5m
|
$90.9m
|
$126.4m
|
$180.2m
|
$186.6m
|
$131.7m
|
|
Additional Financial Items
|
|
|
|
|
|
|
|
|
|
|
Applicable Tax Rate
|
|
—
|
$0
|
—
|
$0
|
—
|
—
|
—
|
—
|
|
Depreciation Right of Use Assets
|
|
—
|
—
|
$567k
|
$827k
|
$1.3m
|
$3.6m
|
$3.4m
|
$5.0m
|
|
Finance Income
|
|
—
|
$8.7m
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Profit Loss Attributable To Noncontrolling Interests
|
|
—
|
$2.0m
|
$877k
|
$3.0m
|
$3.3m
|
$1.4m
|
$3.0m
|
($3.4m)
|
|
Profit Loss Attributable To Owners Of Parent
|
|
—
|
($18.4m)
|
$3.4m
|
($6.9m)
|
($7.2m)
|
$18.8m
|
$3.2m
|
($55.4m)
|
|
Profit Loss Before Tax
|
|
$25.2m
|
($9.4m)
|
$6.4m
|
$10.5m
|
$14.1m
|
$19.1m
|
$10.0m
|
($57.6m)
|
|
Profit Loss From Operating Activities
|
|
$15.7m
|
$32.1m
|
$39.1m
|
$38.4m
|
$39.9m
|
$54.2m
|
$44.8m
|
($2.2m)
|
|
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method
|
|
($2.1m)
|
$1.0m
|
$2.5m
|
$997k
|
$1.1m
|
$1.2m
|
$4.0m
|
($1.1m)
|
|
Initial recognition and changes in the fair value of biological assets at the point of harvest
|
|
—
|
$280k
|
$717k
|
$2.8m
|
$6.4m
|
$611k
|
($46k)
|
$1.8m
|
|
Changes in the net realizable value of agricultural products after harvest
|
|
—
|
—
|
—
|
—
|
($43k)
|
($4.4m)
|
($2.4m)
|
($1.5m)
|
|
Share of profit or loss of joint ventures and associates
|
|
($2.1m)
|
$1.0m
|
$2.5m
|
$997k
|
$1.1m
|
$1.2m
|
$4.0m
|
($1.1m)
|
|
Operating (loss)/ profit
|
|
$15.7m
|
$32.1m
|
$39.1m
|
$38.4m
|
$39.9m
|
$54.2m
|
$44.8m
|
($2.2m)
|
|
Other financial results
|
|
($23.8m)
|
($17.1m)
|
($11.8m)
|
($6.6m)
|
($7.9m)
|
($11.3m)
|
($7.9m)
|
($26.5m)
|
|
(Loss)/ Profit before income tax
|
|
($25.2m)
|
($9.4m)
|
$6.4m
|
$10.5m
|
$14.1m
|
$19.1m
|
$10.0m
|
($57.6m)
|
|
Income tax
|
|
$10.9m
|
($7.0m)
|
($2.2m)
|
($14.4m)
|
($18.0m)
|
$1.1m
|
($3.8m)
|
($1.3m)
|
|
(Loss)/ Profit for the year
|
|
($14.3m)
|
($16.4m)
|
$4.2m
|
($3.8m)
|
($3.9m)
|
$20.2m
|
$6.3m
|
($58.8m)
|
|
Equity holders of the parent
|
|
($33.9m)
|
($14.3m)
|
($5.2m)
|
$1.6m
|
$22.1m
|
$17.9m
|
$2.8m
|
($56.0m)
|
|
Non-controlling interests
|
|
($12.2m)
|
$1.9m
|
($223k)
|
$4.7m
|
$9.1m
|
$1.4m
|
$2.7m
|
($3.6m)
|
|
Basic loss attributable to ordinary equity holders of the parent
|
|
—
|
($0.60)
|
$0.09
|
($0)
|
($0)
|
$0
|
$0
|
($1)
|
|
Diluted loss attributable to ordinary equity holders of the parent
|
|
($0)
|
($1)
|
$0
|
($0)
|
($0)
|
$0
|
$0
|
($1)
|
|
Other comprehensive (loss)
|
|
($31.8m)
|
$3.9m
|
($9.7m)
|
$10.1m
|
$35.2m
|
($836k)
|
($787k)
|
($714k)
|
|
Items that may be subsequently reclassified to (loss)/ profit
|
|
($43.7m)
|
$5.3m
|
($13.6m)
|
$12.7m
|
$40.5m
|
$632k
|
($787k)
|
($714k)
|
|
Foreign exchange differences on translation of foreign operations from joint ventures
|
|
($13.9m)
|
$11k
|
($3.5m)
|
$2.7m
|
$7.8m
|
($47k)
|
($238)
|
—
|
|
Foreign exchange differences on translation of foreign operations
|
|
($29.8m)
|
$5.2m
|
($10.1m)
|
$10.1m
|
$32.6m
|
$678k
|
($787k)
|
($714k)
|
|
Items that will not be subsequently reclassified to loss and profit
|
|
$11.9m
|
($1.3m)
|
$3.9m
|
($2.7m)
|
($5.3m)
|
($1.5m)
|
—
|
—
|
|
Revaluation of property, plant and equipment, net of tax, of joint ventures and associates 1
|
|
$1.8m
|
($1.4m)
|
$3.4m
|
($2.3m)
|
($4.7m)
|
($1.3m)
|
—
|
—
|
|
Total comprehensive (loss)/ profit
|
|
($46.1m)
|
($12.5m)
|
($5.4m)
|
$6.2m
|
$31.3m
|
$19.3m
|
$5.5m
|
($59.6m)
|
|
Basic Earnings (Loss) Per Share
|
|
—
|
($0.60)
|
$0.09
|
($0.18)
|
($0.17)
|
$0.30
|
$0.05
|
($0.88)
|
|
Diluted Earnings (Loss) Per Share
|
|
($0)
|
($1)
|
$0.09
|
($0.18)
|
($0.17)
|
$0.30
|
$0.05
|
($0.88)
|
|
Research And Development Expense
|
|
—
|
$3.7m
|
$4.2m
|
$5.6m
|
$6.9m
|
$15.3m
|
$17.2m
|
$14.9m
|
|
Research and development expenses
|
|
($4.0m)
|
($3.7m)
|
($4.2m)
|
($5.6m)
|
($6.9m)
|
($15.3m)
|
($17.2m)
|
($14.9m)
|
|
Selling, General and Administrative Expense
|
|
$35.3m
|
$39.2m
|
$38.3m
|
$47.6m
|
$77.5m
|
$113.0m
|
$123.7m
|
$123.1m
|
|
Selling, general and administrative expenses
|
|
($35.3m)
|
($39.2m)
|
($38.3m)
|
($47.6m)
|
($77.5m)
|
($113.0m)
|
($123.7m)
|
($123.1m)
|
|
Administrative Expense
|
|
—
|
$384k
|
$359k
|
$681k
|
—
|
—
|
—
|
—
|
|
Current Tax Expense (Income)
|
|
—
|
$2.1m
|
$4.1m
|
$10.1m
|
$19.0m
|
$1.3m
|
$8.9m
|
$1.4m
|
|
Deferred Tax Expense (Income)
|
|
—
|
$4.8m
|
($1.9m)
|
$4.3m
|
($1.0m)
|
($2.4m)
|
($5.1m)
|
($135k)
|
|
Deferred Tax Expense (Income) Recognised In Profit Or Loss
|
|
—
|
$9.4m
|
$1.9m
|
($4.3m)
|
$1.0m
|
$2.4m
|
$5.1m
|
$135k
|
|
Expense From Share-Based Payment Transactions With Employees
|
|
—
|
$20.9m
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Finance Costs
|
|
—
|
$26.1m
|
$20.9m
|
$21.2m
|
$17.9m
|
$23.8m
|
$26.9m
|
$28.8m
|
|
Other Operating Income Expense
|
|
$613k
|
$366k
|
($307k)
|
($279k)
|
($3.3m)
|
$1.1m
|
($2.5m)
|
$6.8m
|
|
Professional Fees Expense
|
|
—
|
$8.0m
|
$3.3m
|
$8.5m
|
$9.3m
|
$16.1m
|
$10.7m
|
$11.3m
|
|
Other income or expenses, net
|
|
$613k
|
$366k
|
($307k)
|
($279k)
|
($3.3m)
|
$1.1m
|
($2.5m)
|
$6.8m
|
|
Financial cost
|
|
($17.2m)
|
($24.4m)
|
($20.9m)
|
($21.2m)
|
($17.9m)
|
($23.8m)
|
($26.9m)
|
($28.8m)
|
|
Income Tax Expense Continuing Operations
|
|
—
|
$7.0m
|
$2.2m
|
$14.4m
|
$18.0m
|
($1.1m)
|
$3.8m
|
$1.3m
|